Clinical trials: Refractory Ulcerative Colitis
Severe Ulcerative Colitis
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis
The purpose of this study is to evaluate the safety and tolerability of visilizumab in patients with severe ulcerative colitis that has failed to respond to steroid therapy.
- Trial name
- NCT00267306
- Testing
- Visilizumab
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- Facet Biotech
Crohn's Disease (CD), Ulcerative Colitis (UC)
Upadacitinib for Refractory IBD in Asian Children and Elderly: Age-Stratified Analysis
This single-center, retrospective study aims to evaluate the effectiveness and safety of upadacitinib (UPA) in Asian pediatric patients with refractory Crohn's disease (CD) and elderly patients with refractory ulcerative colitis…
- Conditions
- Crohn's Disease (CD), Ulcerative Colitis (UC), Refractory Crohn's Disease, Refractory Ulcerative Colitis
- Trial name
- UPA-AGE (NCT06922331)
- Testing
- Upadacitinib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Crohn Disease, Ulcerative Colitis
Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases
A Clinical Study on the Safety and Effectiveness of Targeting CD7 Chimeric Antigen Receptor T Cells in the Treatment of Autoimmune Diseases
- Conditions
- Crohn Disease, Ulcerative Colitis, Dermatomyositis, Still Disease
- Trial name
- NCT05239702
- Testing
- CD7 CAR T-cells
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Zhejiang University
Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases
COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)
The purpose of the study is to compare the clinical effectiveness and safety of newer inflammatory bowel disease (IBD) medications in anti-tumor necrosis factor (TNF) refractory patients with pediatric IBD (PIBD).
- Conditions
- Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
- Trial name
- COMPARE (NCT07198113)
- Where
- 4 sites in United States
- Volunteers
- 1,100 people
- Sponsor
- University of North Carolina, Chapel Hill
Ulcerative Colitis
CT to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis
The primary endpoint will be evaluated through the following variables: PUCAI score, IFX levels, and steroid treatment. Clinical response to IFX will be evaluated through the PUCAI score.
- Trial name
- NCT05430412
- Testing
- Adacolumn
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 15 people
- Sponsor
- Adacyte Therapeutics SL
Ulcerative Colitis
Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients
This study consists of a 2-week placebo-controlled double-blind inter-group efficacy study in moderate to severe refractory ulcerative colitis (UC) patients followed by a maximum of 12-week open-label efficacy and safety study in…
- Trial name
- NCT00347048
- Testing
- tacrolimus
- Where
- 6 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Astellas Pharma Inc
Inflammatory Bowel Diseases, Crohn's Disease
Thalidomide in Pediatric Inflammatory Bowel Diseases.
Several open-label studies reported thalidomide efficacy in inducing clinical remission and steroid tapering in refractory Inflammatory Bowel diseases (IBD), both in adults and in children.
- Conditions
- Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis
- Trial name
- TALIBDP (NCT00720538)
- Testing
- Thalidomide
- Where
- 7 sites in Italy
- Volunteers
- 84 people
- Sponsor
- IRCCS Burlo Garofolo
Ulcerative Colitis
Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients
Patients with severe refractory ulcerative colitis (UC) or those who received placebo in study F506-CL-1107 will receive tacrolimus for a maximum of 12 weeks. Safety and efficacy will be evaluated.
- Trial name
- NCT00643071
- Testing
- Tacrolimus
- Where
- 6 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Astellas Pharma Inc
Colitis, Ulcerative, Bowel Diseases, Inflammatory
Anti-TNF Therapy for Refractory Colitis in Hospitalized Children
This multicenter study is being conducted to determine whether infliximab exposure after an initial infusion is predictive of early clinical response in hospitalized pediatric patients with severe steroid-refractory UC or IBD-U.
- Trial name
- ARCH (NCT02799615)
- Testing
- Infliximab
- Where
- 7 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Clostridium Difficile Infection, Ulcerative Colitis
Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis
Fecal Microbiota Transplantation will be offered to eligible C. difficile patients (does not require Investigational New Drug designation) and to eligible ulcerative colitis or indeterminate colitis patients as Investigational…
- Conditions
- Clostridium Difficile Infection, Ulcerative Colitis, Indeterminate Colitis
- Trial name
- FMT (NCT03268213)
- Testing
- Fecal Microbial Transplantation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Stony Brook University
Ulcerative Colitis
Antimicrobial Therapy for Ulcerative Colitis (UC)
The Aim of this randoized controlled pilot study is to find a better treatment strategy for active UC based on the recent knowledge regarding the microbiota in UC and the beneficial or detrimental effects of antibiotics in…
- Trial name
- UC (NCT03986996)
- Testing
- amoxicillin, metronidazole and doxycycline, amoxicillin and doxycyclin
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Wolfson Medical Center